

# MNWR

MORBIDITY AND MORTALITY WEEKLY REPORT

- 501 Imported Cholera Associated with a Newly Described Toxigenic *Vibrio cholerae* O139 Strain — California, 1993
- 504 Smoking Cessation During Previous Year Among Adults — United States
- 507 Availability of Comprehensive Adolescent Health Services — United States, 1990
- 516 *Salmonella* Serotype Tennessee in Powdered Milk Products and Infant Formula — Canada and United States
- 517 Update: Hantavirus Infection — United States

## Emerging Infectious Diseases

### **Imported Cholera Associated with a Newly Described Toxigenic *Vibrio cholerae* O139 Strain — California, 1993**

Epidemics of cholera-like illness caused by a previously unrecognized organism occurred recently in southern Asia (1). This report documents the first case of cholera imported into the United States that was caused by this organism, the newly described toxigenic *Vibrio cholerae* O139 strain.

On February 5, 1993, a 48-year-old female resident of Los Angeles County sought care at a local outpatient health-care facility for acute onset of watery diarrhea and back pain. A few hours before seeking medical care, she had returned to the United States from a 6-week visit with relatives in Hyderabad, India.

Her diarrheal illness began in India on February 4 and increased in severity while she traveled to the United States. She reported a maximum of 10 watery stools per day but no vomiting, visible blood or mucous in her stools, or documented fever. The patient was prescribed trimethoprim-sulfamethoxazole without rehydration treatment and recovered uneventfully. Duration of illness was approximately 4 days. No secondary illness occurred among family members.

When the patient sought medical care, the physician suspected cholera, and a culture of a stool specimen obtained from the patient at that time yielded colonies suspected of being *V. cholerae*. This was confirmed by the Los Angeles County Public Health Laboratory. The isolate was identified as *V. cholerae* non-O1. The isolate produced cholera toxin by Y-1 adrenal cell assay and latex agglutination in the California State Public Health Laboratory. Testing at CDC identified the isolate as toxigenic *V. cholerae* serogroup O139, resistant to trimethoprim-sulfamethoxazole.

Before this illness, the patient had been in good health. In Hyderabad, she stayed with relatives and did not travel outside the city. Although the source of her infection was not confirmed, on January 30, the patient had eaten fried shrimp and prawns purchased from a local market and prepared by relatives. She also recalled drinking a half glass of unbottled water in Hyderabad on February 3.

*Reported by: M Tormey, MPH, L Mascola, MD, L Kilman, Los Angeles County Dept of Health Svcs, Los Angeles; P Nagami, MD, Southern California Permanente Medical Group, Los Angeles; E DeBess, DVM, S Abbott, GW Rutherford, III, MD, State Epidemiologist, California Dept of*

*Imported Cholera — Continued*

*Health Svcs. Foodborne and Diarrheal Diseases Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, CDC.*

**Editorial Note:** In October 1992, an epidemic of cholera-like illness began in Madras, India, associated with an atypical strain of *V. cholerae* (2). In early 1993, similar epidemics began in Calcutta (with more than 13,000 cases) and in Bangladesh (with more than 10,000 cases and 500 deaths) caused by similarly atypical strains of *V. cholerae* (3,4). These strains could not be identified as any of the 138 known types of *V. cholerae* and have been designated as a new serogroup, O139 (5). Although the extent of the ongoing epidemic in southern Asia is unclear, this strain is now associated with epidemic cholera-like illness along a 1000-mile coastline of the Bay of Bengal (from Madras, India, to Bangladesh) and appears to have largely replaced *V. cholerae* O1 strains in affected areas.

The emergence of this new cause of epidemic cholera represents an important shift in the epidemiology of this infectious disease (6). Until 1993, the only recognized causes of epidemic cholera were *V. cholerae* strains that were part of serogroup O1. *V. cholerae* isolates from other serogroups (i.e., non-O1) were recognized as causes of sporadic diarrheal and invasive infections but were not considered to have epidemic potential. The relation of the new non-O1 serogroup to typical O1 strains is unclear; except for the presence of O1 antigen, the strains are nearly identical in most characteristics.

Descriptions of the symptoms associated with *V. cholerae* O139 infection suggest it is indistinguishable from cholera caused by *V. cholerae* O1 and should be treated with the same rapid fluid replacement (7). Although the illness may be severe, it is treatable with oral and intravenous rehydration therapy. The new organism has been susceptible to tetracycline, which is the recommended antibiotic for treatment of cholera. However, the organism is reportedly resistant to trimethoprim-sulfamethoxazole and furazolidone, other antibiotics used to treat cholera.

Health-care providers should consider the new strain as a possible cause of cholera-like illness in persons returning from the Indian subcontinent. Although previous cases were reported from Madras and Calcutta in India and from Bangladesh, this report suggests that Hyderabad, India—which is inland—is also affected. Because of effective sewerage and water treatment, further spread of this strain is unlikely in the United States. However, the potential for epidemic cholera caused by *V. cholerae* O139 exists for much of the developing world, and further spread to other parts of Asia is probable.

The emergence of this new strain has at least three other major public health implications. First, it expands the definition of cholera beyond the illness caused exclusively by toxigenic *V. cholerae* of serogroup O1. Because it appears to cause the same illness and to have similar epidemic potential, the World Health Organization has asked all nations to report illnesses caused by this strain as cholera (1). In the United States, clinicians, laboratorians, and public health authorities should report infections with toxigenic *V. cholerae* O139 as cholera, in addition to cases of toxigenic *V. cholerae* O1 infection.

Second, the rapid spread of the *V. cholerae* O139 epidemic in southern Asia, even among adults previously exposed to cholera caused by *V. cholerae* O1, suggests that preexisting immunity to toxigenic *V. cholerae* O1, whether the result of natural infection or cholera vaccine, offers little or no protective benefit. Travelers to areas affected

*Imported Cholera — Continued*

by this epidemic should exercise particular care in selecting food and drink and should not assume that cholera vaccination is protective against the *V. cholerae* O139 strain.

Third, laboratory identification methods for *V. cholerae* O1 depend on detection of the O1 antigen on the surface of the bacterium, and therefore do not identify this new strain. A specific diagnostic antiserum for *V. cholerae* O139 is being prepared for use in U.S. public health laboratories and will be distributed soon. Without such antiserum, this strain might be confused with other non-O1 *V. cholerae* isolates unrelated to the newly described O139 strain that occasionally cause infections in the United States.

In 1989, a pilot surveillance effort in four states determined that the reported infection rate for non-O1 *V. cholerae* was 1 per 1 million population (8). Although non-O1 strains can cause illness, non-O1 strains other than the newly described O139 have not been implicated as a cause of epidemics and are not considered a major public health problem. Accordingly, CDC recommends that:

1. Sporadic clinical isolates of non-O1 *V. cholerae* should be referred to a state public health laboratory for further characterization if there is an epidemiologic link to areas of the world known to be affected by O139 (currently India and Bangladesh); if the disease is typical of severe cholera (i.e., watery diarrhea with life-threatening dehydration); or if the isolate has been linked to an outbreak (i.e., more than one linked case) of diarrheal illness.
2. Physicians should ask that specimens from persons with suspected cholera be cultured on thiosulfate-citrate-bile salts-sucrose (TCBS) medium for isolation of *V. cholerae*. All cases of suspected cholera should be reported immediately to local and state health departments.

*References*

1. World Health Organization. Epidemic diarrhea due to *Vibrio cholerae* non-O1. *Wkly Epidemiol Rec* 1993;68:141-2.
2. Ramamurthy T, Garg S, Sharma R, et al. Emergence of novel strain of *Vibrio cholerae* with epidemic potential in southern and eastern India [Letter]. *Lancet* 1993;341:703-4.
3. Albert MJ, Siddique AK, Islam MS, et al. Large outbreak of clinical cholera due to *Vibrio cholerae* non-O1 in Bangladesh [Letter]. *Lancet* 1993;341:704.
4. Bhattacharya MK, Bhattacharya SK, Garg S, et al. Outbreak of *Vibrio cholerae* non-O1 in India and Bangladesh [Letter]. *Lancet* 1993;341:1346-7.
5. Shimada T, Balakrish Nair G, Deb BC, et al. Outbreak of *Vibrio cholerae* non-O1 in India and Bangladesh [Letter]. *Lancet* 1993;341:1347.
6. CDC. Emerging infectious diseases—introduction. *MMWR* 1993;42:257.
7. Swerdlow DL, Ries AA. Cholera in the Americas: guidelines for the clinician. *JAMA* 1992;267:1495-9.
8. Levine WC, Griffin PM, Gulf Coast *Vibrio* Working Group. *Vibrio* infections on the Gulf Coast: results of first year of regional surveillance. *J Infect Dis* 1993;167:479-83.

## *Progress in Chronic Disease Prevention*

### **Smoking Cessation During Previous Year Among Adults — United States, 1990 and 1991**

Although most smokers in the United States report that they want to stop using cigarettes (1), 46 million persons aged  $\geq 18$  years continue to smoke (2). Current information about factors predictive of smoking or cessation is required to develop and assess measures effective in reducing smoking prevalence. To characterize the patterns of attempting to quit smoking and smoking cessation among U.S. adults during 1990 and 1991, CDC's National Health Interview Survey–Health Promotion and Disease Prevention (NHIS–HPDP) supplement collected self-reported information on cigarette smoking from a representative sample of the U.S. civilian, noninstitutionalized population aged  $\geq 18$  years. This report summarizes findings from this survey.

The overall response rate for the 1991 NHIS–HPDP was 87.8%. Participants ( $n=43,732$ ) were asked: "Have you smoked at least 100 cigarettes in your entire life?" Those who responded "yes" (i.e., ever smokers) were asked: "Around this time last year, were you smoking cigarettes every day, some days, or not at all?" They were then asked: "Do you smoke cigarettes now?" Those who responded "yes" were asked: "Do you now smoke cigarettes every day or some days?"; those who responded "no" were asked: "Do you now smoke cigarettes not at all or some days?" The time period from the reference time 1 year earlier (about which the ever smoker reported the frequency of smoking) to the date of interview was considered the study period.

Current every-day smokers were persons who stated that they smoked now and that they smoked every day. Those who stated that they did not smoke at all at the time of the survey were considered former smokers. Some-day smokers were those who smoked on some days. These definitions differ slightly from traditional definitions used by CDC's National Center for Health Statistics because they incorporate the concepts of every-day and some-day smoking. Current every-day smokers who stated that they quit for at least 1 day during the past year, some-day smokers, and former smokers were all considered to have been abstinent from smoking for at least 1 day during the study period. Those former smokers who quit smoking cigarettes for at least 1 month at the time of the survey in 1991 were considered to have maintained abstinence.

For this analysis, three racial/ethnic categories were used: white, non-Hispanic; black, non-Hispanic; and Hispanic. Other racial/ethnic groups were not included because numbers were too small for meaningful analysis. Data were adjusted for nonresponse and weighted to provide national estimates. Investigators used the Software for Survey Data Analysis (SUDAAN) to calculate 95% confidence intervals (CIs) and adjusted odds ratios (3).

Among U.S. adults who had smoked at least 100 cigarettes during their lifetimes as of 1991, an estimated 40.5 million smoked cigarettes every day at the beginning of the study period. Approximately 17.0 million (42.1%) of these did not smoke cigarettes for at least 1 day during the subsequent 12 months. Hispanics (52.1% [95% CI=46.4%–57.8%]) and blacks (48.7% [95% CI=45.2%–52.2%]) were more likely than whites (40.3% [95% CI=39.0%–41.6%]) to quit smoking cigarettes for at least 1 day. Abstinance

*Smoking Cessation — Continued*

for at least 1 day, by age, was highest among persons aged 18–24 years (56.7% [95% CI=52.9%–60.5%]) and, by education, was lowest among those with <12 years of education (36.5% [95% CI=34.1%–38.9%]). These relations were also evident after statistical adjustment was made for other sociodemographic variables (Table 1).

Among persons who reported that they did not smoke cigarettes for at least 1 day during the previous year, 13.8% (2.3 million) were abstinent for 1 month or more at the end of the study period. Hispanics (16.3% [95% CI=10.3%–22.2%]) and whites (14.0% [95% CI=12.6%–15.4%]) were more likely than blacks (7.9% [95% CI=5.1%–10.7%]) to remain abstinent; this difference remained after statistical adjustments were made for sex, age, education, and poverty status (Table 1). Persons aged  $\geq 65$  years (19.4% [95% CI=14.6%–24.2%]) and college graduates (18.8% [95% CI=14.9%–22.7%]) were the most likely to maintain abstinence. Persons at or above the poverty level\* (14.8% [95% CI=13.4%–16.3%]) were more likely to maintain abstinence than those below the poverty level (7.5% [95% CI=4.7%–10.3%]).

Of all persons who were daily smokers at the beginning of the study period, 5.7% quit smoking and maintained abstinence for at least 1 month. Among persons who were daily smokers at the beginning of the study period, college graduates and persons at or above the poverty level were more likely than those with fewer years of formal education and persons below the poverty level, respectively, to abstain from cigarette smoking for 1 month or more.

*Reported by: Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion; Div of Health Interview Statistics, National Center for Health Statistics, CDC.*

**Editorial Note:** The findings from this survey indicate that, in 1990 and 1991, approximately 42% of daily smokers abstained from smoking cigarettes for at least 1 day but that approximately 86% of these persons subsequently resumed smoking. The high relapse rate is likely because of the addictive nature of nicotine (4). However, because relapse occurs later in the process of maintenance, the overall rate of cessation will be lower than suggested by this report. From 1974 through 1991, an estimated 45.8–53.5 million persons aged  $\geq 18$  years smoked; of these, approximately 1.2 million persons became former smokers each year (CDC, unpublished data), suggesting that approximately 2.5% of U.S. smokers quit smoking permanently each year.

Education level and age are both important predictors for cessation attempts and maintaining abstinence. The findings in this report are consistent with previous studies noting that increasing level of education correlates directly with smoking cessation prevalence and inversely with prevalence of smoking (2). In addition, although persons aged  $\geq 65$  years were less likely to abstain for 1 day, those who did abstain were the most likely to be successful in maintaining abstinence during the study period. This finding may suggest that older persons may be more motivated than younger persons to overcome nicotine addiction (5).

In 1991, among the three racial/ethnic groups studied, the maintenance rate of abstinence from smoking was higher for Hispanics and whites than for blacks. Potential explanations for the high relapse rate among blacks include the use of cigarettes with higher tar and nicotine yields (4), a higher prevalence of nicotine dependency among

\*Poverty statistics are based on definitions developed by the Social Security Administration that include a set of income thresholds that vary by family size and composition.

*Smoking Cessation — Continued*

persons who smoke (6), and comparatively limited access to preventive health services (4,7). Smoking-cessation programs are important for all racial/ethnic groups. Programs have been developed for Asian/Pacific Islanders, American Indians/Alaskan Natives (T. Stratton, California Department of Health Services, personal communication, 1993), and Hispanics (8). The elevated prevalence of cigarette smoking among (2) and the higher smoking-attributable death rate for (9) blacks indicate the need for

**TABLE 1. Adjusted odds ratios (AORs)\* for three measures of abstinence from cigarette smoking during the previous year, by sex, race/ethnicity,<sup>†</sup> age group, level of education,<sup>§</sup> and poverty status<sup>¶</sup> — United States, National Health Interview Survey, 1991\*\***

Category	Abstinence for ≥1 day		Maintenance among abstainers		Maintenance <sup>††</sup> among all persons who were daily smokers 1 year earlier	
	AOR	(95% CI <sup>§§</sup> )	AOR	(95% CI)	AOR	(95%CI)
<b>Sex</b>						
Male	1.0	Referent	1.0	Referent	1.0	Referent
Female	1.0	(0.9–1.2)	1.1	(0.9–1.3)	1.0	(0.9–1.3)
<b>Race/Ethnicity</b>						
White, non-Hispanic	1.0	Referent	1.0	Referent	1.0	Referent
Black, non-Hispanic	1.6	(1.3–1.8)	0.6	(0.4–0.9)	0.8	(0.5–1.2)
Hispanic	1.7	(1.3–2.1)	1.3	(0.9–2.1)	1.7	(1.1–2.7)
<b>Age group (yrs)</b>						
18–24	1.0	Referent	1.0	Referent	1.0	Referent
25–44	0.5	(0.5–0.6)	0.9	(0.6–1.3)	0.7	(0.5–0.9)
45–64	0.4	(0.3–0.5)	0.9	(0.6–1.4)	0.6	(0.4–0.8)
≥65	0.5	(0.4–0.6)	1.5	(1.0–2.4)	0.9	(0.6–1.4)
<b>Education (yrs)</b>						
<12	1.0	Referent	1.0	Referent	1.0	Referent
12	1.3	(1.1–1.5)	1.0	(0.7–1.4)	1.2	(0.9–1.6)
13–15	1.6	(1.3–1.8)	1.1	(0.8–1.5)	1.4	(1.0–1.9)
≥16	1.6	(1.3–2.0)	1.5	(1.0–2.2)	1.9	(1.3–2.7)
<b>Poverty status</b>						
At/above poverty level	1.0	Referent	1.0	Referent	1.0	Referent
Below poverty level	1.0	(0.8–1.1)	0.5	(0.3–0.8)	0.5	(0.4–0.8)
Unknown	0.7	(0.6–0.9)	0.9	(0.6–1.4)	0.8	(0.5–1.1)

\*The odds ratios presented for each sociodemographic variable are adjusted for the other four sociodemographic variables in the table.

<sup>†</sup>Excludes 268 respondents of other or unknown race; race/ethnicity and education were both unknown for four respondents.

<sup>§</sup>Excludes 24 respondents of unknown education status.

<sup>¶</sup>Poverty statistics are based on definitions developed by the Social Security Administration that include a set of income thresholds that vary by family size and composition.

\*\* Sample size=9415.

<sup>††</sup>Abstinence from smoking cigarettes for at least 1 month preceding the interview. Excludes 92 respondents who abstained from cigarettes for <1 month or for whom duration of abstinence was unknown.

<sup>§§</sup>Confidence interval.

*Smoking Cessation — Continued*

specific efforts to reduce the adverse impact of tobacco use among blacks. CDC and the National Medical Association are initiating a targeted mass media campaign in July 1993 called "Legends" that contrasts the deaths of black civil-rights leaders to preventable smoking-related deaths. In addition, a toll-free telephone number ([800] 232-1311) is available to request a smoking-cessation guide, *Pathways to Freedom*. This guide addresses important topics including nicotine addiction, possible misconceptions about the safety of smoking menthol cigarettes, stress-reduction techniques, preparing for quitting, relapse-prevention techniques, and the cultural meaning of smoking (6).

*References*


1. Thomas RM, Larsen MD. Smoking prevalence, beliefs, and activities by gender and other demographic indicators. Princeton, New Jersey: The Gallup Organization, Inc, 1993.
2. CDC. Cigarette smoking among adults—United States, 1991. *MMWR* 1993;42:230–3.
3. Shah BV. Software for Survey Data Analysis (SUDAAN) version 5.30 [Software documentation]. Research Triangle Park, North Carolina: Research Triangle Institute, 1989.
4. Public Health Service. The health consequences of smoking: nicotine addiction. Rockville, Maryland: US Department of Health and Human Services, Public Health Service, 1988; DHHS publication no. (CDC)88-8406.
5. Hatziafreu EJ, Pierce JP, Lefkopoulou M, et al. Quitting smoking in the United States in 1986. *J Natl Cancer Inst* 1990;82:1402–6.
6. Royce JM, Hymowitz N, Corbett K, Hartwell TD, Orlandi MA, for the COMMIT Research Group. Smoking cessation factors among African Americans and whites. *Am J Public Health* 1993;83:220–6.
7. Hymowitz N, Sexton M, Ockene J, Grandits G, for the MRFIT Research Group. Baseline factors associated with smoking cessation and relapse. *Prev Med* 1991;20:590–601.
8. Marin G, Marin BV, Perez-Stable EJ, Sabogal F, Otero-Sabogal R. Changes in information as a function of a culturally appropriate smoking cessation community intervention for Hispanics. *Am J Community Psychol* 1990;18:847–64.
9. CDC. Smoking-attributable mortality and years of potential life lost—United States, 1988. *MMWR* 1991;40:62–3,69–71.

*Current Trends***Availability of Comprehensive Adolescent Health Services —  
United States, 1990**

The national health objectives for the year 2000 target the reduction of behaviors that place adolescents at risk for human immunodeficiency virus (HIV) infection and other sexually transmitted diseases, unintended pregnancies, and other health problems (1). Although clinical preventive services are an important component of health-promotion and disease-prevention programs required to achieve these objectives (2), adolescents and young adults are less likely to have access to health care than younger and older persons (2,3). To characterize comprehensive health-service programs for adolescents (i.e., persons aged 13–19 years) and whether such programs provide targeted services to adolescents at risk for HIV infection or infected with HIV, the Center for Health Promotion and Disease Prevention at the University of North Carolina at Chapel Hill conducted a national survey of such programs in 1991. This report summarizes the results of this survey.

(Continued on page 513)

**FIGURE I. Notifiable disease reports, comparison of 4-week totals ending July 3, 1993, with historical data — United States**



\*The large apparent decrease in reported cases of measles (total) reflects dramatic fluctuations in the historical baseline. (Ratio (log scale) for week twenty-six is 0.02918).

<sup>†</sup> Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

**TABLE I. Summary — cases of specified notifiable diseases, United States, cumulative, week ending July 3, 1993 (26th Week)**

	Cum. 1993		Cum. 1993
AIDS*	59,979	Measles: imported	17
Anthrax	-	indigenous	150
Botulism: Foodborne	7	Plague	3
Infant	12	Poliomyelitis, Paralytic <sup>§</sup>	-
Other	2	Psittacosis	29
Brucellosis	38	Rabies, human	-
Cholera	14	Syphilis, primary & secondary	13,163
Congenital rubella syndrome	5	Syphilis, congenital, age < 1 year	-
Diphtheria	-	Tetanus	15
Encephalitis, post-infectious	86	Toxic shock syndrome	120
Gonorrhea	188,249	Trichinosis	8
<i>Haemophilus influenzae</i> (invasive disease) <sup>†</sup>	647	Tuberculosis	9,855
Hansen Disease	88	Tularemia	55
Leptospirosis	17	Typhoid fever	151
Lyme Disease	2,054	Typhus fever, tickborne (RMSF)	84

\*Updated monthly; last update July 3, 1993.

<sup>†</sup>Of 591 cases of known age, 196 (33%) were reported among children less than 5 years of age.

<sup>§</sup>No cases of suspected poliomyelitis have been reported in 1993; 4 cases of suspected poliomyelitis were reported in 1992; 6 of the 9 suspected cases with onset in 1991 were confirmed; the confirmed cases were vaccine associated.



TABLE II. Cases of selected notifiable diseases, United States, weeks ending July 3, 1993, and June 27, 1992 (26th Week)

Reporting Area	AIDS*	Aseptic Menin- gitis	Encephalitis		Gonorrhea		Hepatitis (Viral), by type				Legionel- losis	Lyme Disease
			Primary	Post-in- fectious			A	B	NA,NB	Unspeci- fied		
			Cum. 1993	Cum. 1993	Cum. 1993	Cum. 1993	Cum. 1993	Cum. 1992	Cum. 1993	Cum. 1993		
UNITED STATES	59,979	3,492	261	86	188,249	244,642	10,219	5,800	2,274	304	551	2,054
NEW ENGLAND	2,815	52	4	4	3,902	5,070	154	159	226	5	14	316
Maine	60	10	1	-	42	48	8	9	-	-	4	3
N.H.	66	9	-	2	31	63	13	45	205	1	1	24
Vt.	14	7	2	-	14	14	3	3	2	-	-	1
Mass.	1,491	11	1	2	1,309	1,856	47	59	15	4	5	20
R.I.	192	15	-	-	185	378	49	14	4	-	4	61
Conn.	992	-	-	-	2,321	2,711	34	29	-	-	-	207
MID. ATLANTIC	13,675	320	13	6	20,590	26,198	597	747	164	4	114	1,359
Upstate N.Y.	2,162	131	6	3	4,037	5,675	184	204	94	1	35	984
N.Y. City	7,455	104	1	-	5,067	8,844	177	121	1	-	3	3
N.J.	2,561	-	-	-	3,509	3,661	160	210	49	-	16	137
Pa.	1,497	85	6	3	7,977	8,018	76	212	20	3	60	235
E.N. CENTRAL	4,967	455	77	15	37,417	45,544	994	595	361	8	152	19
Ohio	809	145	26	3	10,015	13,732	161	121	29	-	75	15
Ind.	585	67	6	7	3,787	4,165	420	117	6	1	32	1
Ill.	1,776	87	16	-	12,862	14,604	293	123	21	2	5	1
Mich.	1,290	146	25	5	8,085	10,947	114	229	284	5	32	2
Wis.	507	10	4	-	2,668	2,096	6	5	21	-	8	-
W.N. CENTRAL	2,274	208	11	-	10,006	13,000	1,291	350	101	6	37	39
Minn.	480	47	5	-	1,242	1,523	207	32	3	4	1	4
Iowa	131	45	1	-	602	889	18	12	4	1	5	5
Mo.	1,292	49	-	-	5,651	7,111	832	260	75	1	11	7
N. Dak.	-	5	2	-	25	47	49	-	-	-	1	1
S. Dak.	21	7	3	-	149	87	10	-	-	-	-	-
Nebr.	120	4	-	-	476	754	116	8	9	-	16	2
Kans.	230	51	-	-	1,861	2,589	59	38	10	-	3	20
S. ATLANTIC	12,950	860	46	38	51,292	76,115	647	1,071	278	42	92	243
Del.	235	18	3	-	669	883	7	77	63	-	7	120
Md.	1,425	71	11	-	8,022	7,304	87	143	7	5	23	38
D.C.	774	19	-	-	2,761	3,579	3	14	-	-	12	2
Va.	899	85	15	3	5,684	9,041	71	76	20	16	2	25
W. Va.	46	7	7	-	288	451	4	18	16	-	1	2
N.C.	742	65	9	-	12,420	12,362	31	164	31	-	14	34
S.C.	854	5	-	-	4,842	5,631	7	18	-	1	10	1
Ga.	1,661	62	1	-	4,660	23,945	60	36	22	-	12	-
Fla.	6,314	528	-	35	11,946	12,919	377	525	119	20	11	21
E.S. CENTRAL	1,588	191	9	4	21,223	23,944	123	616	444	1	22	8
Ky.	185	73	4	4	2,286	2,472	64	47	6	-	8	2
Tenn.	640	29	4	-	6,453	7,577	24	510	430	-	11	4
Ala.	490	57	1	-	7,418	8,152	25	56	3	1	1	2
Miss.	273	32	-	-	5,066	5,743	10	3	5	-	2	-
W.S. CENTRAL	6,332	307	20	-	22,202	25,283	935	774	111	83	15	10
Ark.	248	21	-	-	4,314	4,214	27	32	2	1	-	1
La.	806	27	1	-	5,884	6,449	39	101	38	2	2	-
Okla.	542	1	4	-	1,869	2,487	63	126	33	6	9	5
Tex.	4,736	258	15	-	10,135	12,133	806	515	38	74	4	4
MOUNTAIN	2,789	209	13	4	5,437	6,146	2,083	289	154	51	48	4
Mont.	17	-	-	1	22	56	54	4	-	-	5	-
Idaho	49	6	-	-	87	61	95	23	-	1	1	-
Wyo.	30	3	-	-	41	25	10	13	45	-	5	2
Colo.	925	44	3	-	1,670	2,294	523	32	27	31	4	-
N. Mex.	220	43	3	2	471	451	178	120	50	2	3	1
Ariz.	956	79	5	-	2,045	2,056	711	49	9	7	9	-
Utah	195	7	1	-	170	140	466	23	19	10	7	1
Nev.	397	27	1	1	931	1,063	46	25	4	-	14	-
PACIFIC	12,589	890	68	15	16,180	23,342	3,395	1,199	435	104	57	56
Wash.	882	-	-	-	1,927	2,114	375	105	94	7	8	1
Oreg.	522	-	-	-	940	780	54	21	8	-	-	-
Calif.	11,030	832	65	15	12,825	19,829	2,483	1,057	324	94	44	54
Alaska	20	6	2	-	237	368	435	6	7	-	-	-
Hawaii	135	52	1	-	251	251	48	10	2	3	5	1
Guam	-	2	-	-	38	41	2	2	-	1	-	-
P.R.	1,786	29	-	-	217	91	38	189	22	2	-	-
V.I.	33	-	-	-	61	54	-	2	-	-	-	-
Amer. Samoa	-	-	-	-	22	20	10	-	-	-	-	-
C.N.M.I.	-	2	-	-	45	32	-	-	-	1	-	-

N: Not notifiable

U: Unavailable

C.N.M.I.: Commonwealth of Northern Mariana Islands

\*Updated monthly; last update July 3, 1993.

TABLE II. (Cont'd.) Cases of selected notifiable diseases, United States, weeks ending July 3, 1993, and June 27, 1992 (26th Week)

Reporting Area	Malaria	Measles (Rubeola)					Menin- gococcal infections	Mumps		Pertussis			Rubella		
		Indigenous		Imported*		Total		1993	Cum. 1993	1993	Cum. 1993	Cum. 1992	1993	Cum. 1993	Cum. 1992
		1993	Cum. 1993	1993	Cum. 1993	Cum. 1992									
UNITED STATES	466	2	150	-	17	1,979	1,323	30	923	62	1,301	816	5	113	105
NEW ENGLAND	24	-	42	-	2	50	57	-	5	3	298	76	-	1	6
Maine	1	-	-	-	-	-	5	-	-	-	8	3	-	1	1
N.H.	5	-	-	-	-	12	12	-	-	3	195	22	-	-	-
Vt.	1	-	30	-	1	-	4	-	-	-	42	2	-	-	-
Mass.	2	-	3	-	-	14	17	-	-	-	19	35	-	-	-
R.I.	2	-	-	-	1	20	1	-	2	-	2	-	-	-	4
Conn.	13	-	9	-	-	4	18	-	3	-	32	14	-	-	1
MID. ATLANTIC	88	-	6	-	2	187	169	12	74	13	189	52	4	30	9
Upstate N.Y.	31	-	-	-	1	108	78	2	26	3	80	24	1	5	7
N.Y. City	24	-	2	-	-	43	19	-	-	-	7	9	-	15	-
N.J.	25	-	4	-	1	36	23	-	8	-	21	19	-	6	2
Pa.	8	-	-	-	-	-	49	10	40	10	81	-	3	4	-
E.N. CENTRAL	29	-	1	-	-	36	190	2	135	10	187	75	-	1	7
Ohio	6	-	-	-	-	5	60	2	57	8	119	23	-	1	-
Ind.	4	-	-	-	-	20	32	-	3	2	28	12	-	-	-
Ill.	14	-	1	-	-	8	57	-	29	-	19	12	-	-	7
Mich.	5	-	-	-	-	2	40	-	46	-	18	3	-	-	-
Wis.	-	-	-	-	-	1	1	-	-	-	3	25	-	-	-
W.N. CENTRAL	15	-	1	-	2	8	84	1	27	4	93	57	-	1	5
Minn.	3	-	-	-	-	7	2	-	-	-	43	18	-	-	-
Iowa	1	-	-	-	-	1	15	-	7	-	1	1	-	-	-
Mo.	3	-	1	-	-	-	34	1	15	4	29	24	-	1	1
N. Dak.	2	-	-	-	-	-	3	-	4	-	3	7	-	-	-
S. Dak.	2	-	-	-	-	-	3	-	-	-	1	4	-	-	-
Nebr.	3	-	-	-	-	-	6	-	1	-	5	2	-	-	-
Kans.	1	-	-	-	2	-	21	-	-	-	11	1	-	-	4
S. ATLANTIC	140	-	20	-	3	113	266	12	301	11	140	63	-	8	7
Del.	1	-	3	-	-	1	11	-	4	1	2	-	-	2	-
Md.	14	-	-	-	2	16	25	2	52	4	45	12	-	2	4
D.C.	5	-	-	-	-	-	4	-	-	-	2	-	-	-	-
Va.	10	-	-	-	1	11	25	-	16	4	17	4	-	-	-
W. Va.	2	-	-	-	-	-	11	-	6	-	6	2	-	-	-
N.C.	78	-	-	-	-	24	47	10	177	1	24	14	-	-	-
S.C.	-	-	-	-	-	29	20	-	14	-	5	7	-	-	-
Ga.	3	-	-	-	-	-	57	-	9	-	5	8	-	-	-
Fla.	27	-	17	-	-	32	66	-	23	1	34	16	-	4	3
E.S. CENTRAL	12	-	1	-	-	450	84	-	33	3	61	14	-	-	1
Ky.	-	-	-	-	-	433	17	-	-	-	3	-	-	-	-
Tenn.	7	-	-	-	-	-	18	-	10	-	33	5	-	-	1
Ala.	3	-	1	-	-	-	30	-	18	3	23	8	-	-	-
Miss.	2	-	-	-	-	17	19	-	5	-	2	1	-	-	-
W.S. CENTRAL	11	-	1	-	-	1,031	116	-	132	1	33	111	-	12	6
Ark.	2	-	-	-	-	-	13	-	4	1	3	6	-	-	-
La.	-	-	1	-	-	-	25	-	11	-	5	-	-	1	-
Okla.	4	-	-	-	-	11	10	-	7	-	12	13	-	1	-
Tex.	5	-	-	-	-	1,020	68	-	110	-	13	92	-	10	6
MOUNTAIN	14	-	2	-	-	13	114	-	35	10	97	134	-	4	4
Mont.	2	-	-	-	-	-	11	-	-	-	-	1	-	-	-
Idaho	1	-	-	-	-	-	7	-	5	2	19	17	-	1	1
Wyo.	-	-	-	-	-	1	2	-	2	-	1	-	-	-	-
Colo.	7	-	2	-	-	12	17	-	8	-	33	23	-	-	-
N. Mex.	4	-	-	-	-	-	3	N	N	2	21	29	-	-	-
Ariz.	-	-	-	-	-	-	61	-	6	-	10	48	-	1	2
Utah	-	-	-	-	-	-	6	-	3	6	13	15	-	1	1
Nev.	-	-	-	-	-	-	7	-	11	-	-	1	-	1	-
PACIFIC	133	2	76	-	8	91	243	3	181	7	203	234	1	56	60
Wash.	13	-	-	-	-	10	38	-	8	2	22	58	-	-	6
Oreg.	3	-	-	-	-	-	20	N	N	-	3	14	-	1	1
Calif.	113	1	65	-	3	47	166	2	153	5	168	152	-	33	36
Alaska	-	-	-	-	-	9	11	-	5	-	3	1	-	1	-
Hawaii	4	1	11	-	5	25	8	1	15	-	7	9	1	21	17
Guam	1	U	2	U	-	10	1	U	6	U	-	-	U	-	1
P.R.	-	-	122	-	-	244	6	-	1	-	1	9	-	-	-
V.I.	-	-	-	-	-	-	-	-	3	-	-	-	-	-	-
Amer. Samoa	-	-	1	-	-	-	-	-	-	-	2	6	-	-	-
C.N.M.I.	-	-	-	-	1	-	-	-	11	-	-	1	-	-	-

\*For measles only, imported cases include both out-of-state and international importations.

N: Not notifiable

U: Unavailable

† International

§ Out-of-state

**TABLE II. (Cont'd.) Cases of selected notifiable diseases, United States, weeks ending July 3, 1993, and June 27, 1992 (26th Week)**

Reporting Area	Syphilis (Primary & Secondary)		Toxic-Shock Syndrome	Tuberculosis		Tula- remia	Typhoid Fever	Typhus Fever (Tick-borne) (RMSF)	Rabies, Animal
	Cum. 1993	Cum. 1992	Cum. 1993	Cum. 1993	Cum. 1992	Cum. 1993	Cum. 1993	Cum. 1993	Cum. 1993
UNITED STATES	13,163	17,186	120	9,855	10,386	55	151	84	3,766
NEW ENGLAND	220	325	7	207	168	-	8	1	483
Maine	3	-	2	7	13	-	-	-	-
N.H.	21	25	2	4	-	-	-	-	37
Vt.	1	1	-	3	3	-	-	-	18
Mass.	86	156	2	123	74	-	6	1	80
R.I.	7	18	1	32	13	-	-	-	-
Conn.	102	125	-	38	65	-	2	-	348
MID. ATLANTIC	1,251	2,427	24	2,152	2,526	1	44	8	1,451
Upstate N.Y.	103	206	13	196	311	1	9	1	1,096
N.Y. City	628	1,332	1	1,284	1,474	-	26	-	-
N.J.	174	333	-	348	433	-	6	6	210
Pa.	346	556	10	324	308	-	3	1	145
E.N. CENTRAL	2,118	2,531	36	1,084	1,064	3	14	5	36
Ohio	614	381	15	151	163	1	5	4	4
Ind.	178	121	1	118	87	1	1	-	-
Ill.	796	1,107	5	551	522	-	4	1	4
Mich.	330	529	15	218	246	1	4	-	2
Wis.	200	393	-	46	46	-	-	-	26
W.N. CENTRAL	853	674	9	225	241	16	2	7	187
Minn.	46	44	2	30	60	-	-	-	23
Iowa	32	23	5	24	21	-	-	1	34
Mo.	679	506	-	120	103	6	2	4	5
N. Dak.	-	1	-	2	3	-	-	-	39
S. Dak.	1	-	-	10	14	8	-	2	25
Nebr.	10	19	-	10	13	-	-	-	2
Kans.	85	81	2	29	27	2	-	-	59
S. ATLANTIC	3,522	4,830	13	1,741	1,985	1	20	30	1,043
Del.	69	116	1	21	25	-	1	1	86
Md.	196	359	-	188	139	-	3	3	309
D.C.	201	216	-	85	62	-	-	-	7
Va.	310	395	3	217	145	-	1	2	189
W. Va.	5	9	-	43	31	-	-	-	44
N.C.	991	1,213	3	255	253	-	-	16	40
S.C.	538	654	-	204	214	-	-	1	84
Ga.	588	979	-	380	441	-	1	2	242
Fla.	624	889	6	348	675	1	14	5	42
E. S. CENTRAL	1,862	2,251	4	677	739	3	2	8	47
Ky.	156	72	2	186	199	-	-	3	8
Tenn.	529	633	1	144	164	2	-	3	-
Ala.	406	884	1	237	216	1	2	-	39
Miss.	771	662	-	110	160	-	-	2	-
W.S. CENTRAL	2,755	2,957	2	950	934	24	2	23	299
Ark.	464	465	-	86	82	13	-	-	16
La.	1,215	1,279	-	-	87	-	1	1	1
Okla.	189	124	2	154	70	8	-	22	58
Tex.	887	1,089	-	710	695	3	1	-	224
MOUNTAIN	115	200	7	233	264	2	5	2	49
Mont.	1	3	-	5	-	-	-	-	9
Idaho	-	1	1	6	12	-	-	-	1
Wyo.	4	1	-	1	-	1	-	2	6
Colo.	32	28	1	8	30	-	4	-	1
N. Mex.	19	24	-	35	39	-	-	-	3
Ariz.	51	97	1	116	112	-	1	-	27
Utah	3	5	3	11	42	1	-	-	-
Nev.	5	41	1	51	29	-	-	-	2
PACIFIC	467	991	18	2,586	2,465	5	54	-	171
Wash.	28	49	2	131	156	1	4	-	-
Oreg.	48	25	-	53	60	2	-	-	-
Calif.	387	910	16	2,244	2,093	2	48	-	155
Alaska	2	3	-	25	36	-	-	-	16
Hawaii	2	4	-	133	120	-	2	-	-
Guam	1	2	-	28	34	-	-	-	-
P.R.	293	164	-	93	120	-	-	-	25
V.I.	27	32	-	2	3	-	-	-	-
Amer. Samoa	-	-	-	1	-	-	-	-	-
C.N.M.I.	3	4	-	19	17	-	-	-	-

U: Unavailable

TABLE III. Deaths in 121 U.S. cities,\* week ending  
July 3, 1993 (26th Week)

Reporting Area	All Causes, By Age (Years)						P&I <sup>†</sup> Total	Reporting Area	All Causes, By Age (Years)						P&I <sup>†</sup> Total
	All Ages	≥65	45-64	25-44	1-24	<1			All Ages	≥65	45-64	25-44	1-24	<1	
NEW ENGLAND	559	375	93	52	19	20	50	S. ATLANTIC	922	572	185	107	30	26	30
Boston, Mass.	167	105	31	19	5	7	21	Atlanta, Ga.	U	U	U	U	U	U	U
Bridgeport, Conn.	58	35	9	6	3	5	1	Baltimore, Md.	118	62	27	20	4	5	7
Cambridge, Mass.	22	20	1	-	1	-	2	Charlotte, N.C.	110	65	17	16	8	4	-
Fall River, Mass.	22	14	4	2	1	1	-	Jacksonville, Fla.	111	67	27	14	3	-	5
Hartford, Conn.	49	30	9	5	4	1	4	Miami, Fla.	182	121	35	18	5	3	1
Lowell, Mass.	15	11	-	3	-	1	-	Norfolk, Va.	47	25	9	5	4	4	2
Lynn, Mass.	11	8	3	-	-	-	1	Richmond, Va.	76	48	13	7	3	3	5
New Bedford, Mass.	34	27	5	2	-	-	4	Savannah, Ga.	50	24	13	8	1	4	1
New Haven, Conn.	50	34	8	6	1	1	4	St. Petersburg, Fla.	60	47	8	3	-	2	4
Providence, R.I.	U	U	U	U	U	U	U	Tampa, Fla.	135	84	32	16	2	1	5
Somerville, Mass.	2	2	-	-	-	-	-	Washington, D.C.	U	U	U	U	U	U	U
Springfield, Mass.	46	33	6	4	-	3	4	Wilmington, Del.	33	29	4	-	-	-	-
Waterbury, Conn.	26	17	4	4	-	1	-	E.S. CENTRAL	553	348	116	53	21	15	22
Worcester, Mass.	57	39	13	1	4	-	9	Birmingham, Ala.	104	58	28	8	7	3	3
MID. ATLANTIC	2,583	1,681	501	280	64	56	115	Chattanooga, Tenn.	58	41	9	5	1	2	2
Albany, N.Y.	37	23	7	6	-	1	2	Knoxville, Tenn.	88	56	22	9	1	-	5
Allentown, Pa.	19	18	1	-	-	-	1	Lexington, Ky.	60	40	10	7	1	2	3
Buffalo, N.Y.	101	71	20	5	4	1	1	Memphis, Tenn.	23	19	1	2	1	-	-
Camden, N.J.	38	17	6	5	2	8	1	Mobile, Ala.	76	49	12	8	5	2	5
Elizabeth, N.J.	20	19	1	-	-	-	1	Montgomery, Ala.	47	35	5	6	1	-	1
Erie, Pa.‡	46	39	5	-	1	1	1	Nashville, Tenn.	97	50	29	8	4	6	3
Jersey City, N.J.	35	18	6	9	1	1	-	W.S. CENTRAL	929	598	172	95	37	24	40
New York City, N.Y.	1,300	822	247	179	30	22	48	Austin, Tex.	73	54	7	8	3	1	8
Newark, N.J.	45	18	15	7	2	3	1	Baton Rouge, La.	47	30	10	4	3	-	2
Paterson, N.J.	32	12	8	6	5	1	6	Corpus Christi, Tex.	U	U	U	U	U	U	U
Philadelphia, Pa.	496	332	107	39	8	9	37	Dallas, Tex.	127	73	31	18	2	3	2
Pittsburgh, Pa.‡	64	43	10	6	1	4	5	El Paso, Tex.	77	53	10	8	3	3	7
Reading, Pa.	14	10	3	1	-	-	-	Ft. Worth, Tex.	104	61	20	14	7	2	5
Rochester, N.Y.	120	88	24	3	2	3	3	Houston, Tex.	U	U	U	U	U	U	U
Schenectady, N.Y.	22	17	4	1	-	-	-	Little Rock, Ark.	59	39	14	4	1	1	4
Scranton, Pa.‡	39	27	12	-	-	-	2	New Orleans, La.	86	48	18	15	1	1	-
Syracuse, N.Y.	76	54	10	6	5	1	3	San Antonio, Tex.	228	148	39	20	10	11	10
Trenton, N.J.	37	22	8	5	1	1	2	Shreveport, La.	50	37	8	1	3	1	-
Utica, N.Y.	15	10	4	1	-	-	-	Tulsa, Okla.	78	55	15	3	4	1	2
Yonkers, N.Y.	27	21	3	1	2	-	2	MOUNTAIN	856	557	172	69	38	20	59
E.N. CENTRAL	2,051	1,263	394	209	124	61	105	Albuquerque, N.M.	79	49	18	7	2	3	2
Akron, Ohio	57	39	10	5	2	1	-	Colo. Springs, Colo.	54	36	10	3	3	2	2
Canton, Ohio	31	24	6	1	-	-	7	Denver, Colo.	113	73	25	13	-	2	16
Chicago, Ill.	399	158	95	72	66	8	12	Las Vegas, Nev.	164	92	46	16	8	2	3
Cincinnati, Ohio	194	131	36	12	6	9	19	Ogden, Utah	31	25	5	-	1	-	3
Cleveland, Ohio	140	84	33	13	4	6	1	Phoenix, Ariz.	177	109	35	17	9	7	12
Columbus, Ohio	136	100	20	8	2	6	3	Pueblo, Colo.	22	18	2	1	1	-	-
Dayton, Ohio	96	61	22	7	4	2	2	Salt Lake City, Utah	88	57	12	6	10	3	11
Detroit, Mich.	215	126	37	34	12	6	7	Tucson, Ariz.	128	98	19	6	4	1	10
Evansville, Ind.	37	26	8	2	-	1	-	PACIFIC	1,561	1,013	278	178	48	42	92
Fort Wayne, Ind.	56	37	12	4	3	-	6	Berkeley, Calif.	15	10	3	2	-	-	1
Gary, Ind.	11	5	-	4	2	-	-	Fresno, Calif.	77	48	20	5	3	1	-
Grand Rapids, Mich.	68	40	17	3	5	3	6	Glendale, Calif.	9	7	2	-	-	-	1
Indianapolis, Ind.	200	128	40	14	7	11	8	Honolulu, Hawaii	84	53	20	6	3	2	5
Madison, Wis.	32	21	3	5	1	2	3	Long Beach, Calif.	54	41	4	5	1	3	2
Milwaukee, Wis.	129	91	21	13	2	2	16	Los Angeles, Calif.	198	114	39	37	6	1	4
Peoria, Ill.	42	31	6	1	2	2	7	Pasadena, Calif.	23	15	3	3	1	1	-
Rockford, Ill.	51	38	7	5	1	-	3	Portland, Ore.	132	85	21	17	3	6	7
South Bend, Ind.	32	29	2	-	1	-	3	Sacramento, Calif.	161	113	23	14	3	8	9
Toledo, Ohio	63	45	10	3	4	1	2	San Diego, Calif.	147	89	31	15	10	2	15
Youngstown, Ohio	62	49	9	3	-	1	-	San Francisco, Calif.	171	94	37	32	3	4	-
W.N. CENTRAL	778	550	119	62	30	17	31	San Jose, Calif.	166	125	25	10	3	3	23
Des Moines, Iowa	88	64	14	6	3	1	6	Santa Cruz, Calif.	32	17	7	5	2	1	6
Duluth, Minn.	38	31	5	1	1	-	1	Seattle, Wash.	155	101	21	22	4	7	3
Kansas City, Kans.	47	26	9	7	4	1	1	Spokane, Wash.	50	36	7	1	5	1	6
Kansas City, Mo.	84	62	8	8	4	2	5	Tacoma, Wash.	87	65	15	4	1	2	10
Lincoln, Nebr.	31	23	6	1	1	-	1	TOTAL	10,792 <sup>†</sup>	6,957	2,030	1,105	411	281	544
Minneapolis, Minn.	151	103	25	13	4	6	7								
Omaha, Nebr.	95	62	19	7	2	5	2								
St. Louis, Mo.	121	94	14	7	6	-	3								
St. Paul, Minn.	57	35	12	10	-	-	5								
Wichita, Kans.	66	50	7	2	5	2	-								

\*Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

<sup>†</sup>Pneumonia and influenza.

<sup>‡</sup>Because of changes in reporting methods in these 3 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

<sup>§</sup>Total includes unknown ages.

U: Unavailable.

*Comprehensive Adolescent Health Services — Continued*

Programs providing comprehensive health services to adolescents were identified through a review of publications, mailing lists, adolescent health experts, provider organizations, state and local maternal and child health directors, foundations, and other sources (3). A total of 664 such programs were identified nationwide; at least one program was identified in each state except Montana, Nebraska, North Dakota, South Dakota, Vermont, and Wyoming. To assess the validity of the census, local experts reviewed the lists of identified programs in a sample of four states (Kentucky, Maryland, Mississippi, and Washington) and one large metropolitan area (San Francisco); in each area, 85%–90% of all programs had been identified.

A questionnaire was mailed to the director of each of the 664 programs. Of the 435 (66%) programs that responded, 195 (45%) were based in schools, 96 (22%) in hospitals, 48 (11%) in health centers, 39 (9%) in community centers, 35 (8%) in public health departments, and 22 (5%) in other sites. Nonrespondents were equally distributed among geographic regions of the United States. Programs in rural counties were more likely to respond than programs in metropolitan statistical areas (MSAs) (78% versus 67% [ $p < 0.01$ ]).

The highest proportion (201 [30%]) of all 664 programs was located in nine north-eastern states. Of the 278 programs in urban communities, 83 (30%) were hospital-based programs; 110 (40%), school-based programs; and 10 (4%), health department programs. Of the 115 responding programs in rural communities, 64 (56%) were school-based programs, and 21 (18%) were health department programs.

In 1990, the 435 programs served 605,185 adolescents (median: 720 adolescents per program; range: 13–40,000 adolescents)—approximately 2.5% of the 1990 U.S. adolescent population (24,336,100). These programs reported 2,175,561 patient encounters, for an average of 3.6 visits per adolescent. The ratio of adolescent health programs to the population of adolescents in each state varied widely (Figure 1) (3).

A total of 313 (72%) of the programs received federal funding from different sources, including Medicaid, Title V (Maternal and Child Health), Title X (Family Planning), and Title XX (Family Life Programs). In addition, 326 (75%) received state or local government funding, 109 (25%) received state or local health department funding, and 17 (4%) received state education agency funding; 129 (30%) of the programs received private foundation funding.

Almost all programs provided primary health care (396 [91%]), health education (405 [93%]), and HIV-prevention education (409 [94%]); 200 (46%) provided services during evenings, and 91 (21%) provided services during the weekend. Although 187 (43%) programs targeted sexual risk behavior among adolescents, these programs were no more likely than other programs to provide family-planning services (77% versus 70% [ $p = 0.14$ ]), contraceptives (62% versus 57% [ $p = 0.28$ ]), or HIV-antibody testing (50% versus 43% [ $p = 0.16$ ]) on site. Sixty-four (15%) programs targeted services to adolescents infected with HIV; these programs were more likely to provide HIV testing (67% versus 43% [ $p < 0.01$ ]) and contraceptives on site (75% versus 56% [ $p = 0.006$ ]) than other programs. Programs in health or community centers were more likely to target sexual risk behaviors and adolescents infected with HIV than were programs in other locations.

Although all identified programs had been considered initially to be comprehensive, only 262 (60%) reported that they provided comprehensive services on site. School-based programs were the least likely to provide contraceptive services,


*Comprehensive Adolescent Health Services — Continued*

hospital-based programs were the least likely to provide outreach programs, and health center programs were the least likely to provide mental health services. Programs that considered their services comprehensive were no more likely to provide case management or to have greater coordination of services than were programs that did not consider their services to be comprehensive. Comprehensive programs were more likely to have larger budgets and to receive private foundation funding than were other programs.

*Reported by: JD Klein, MD, Div of Adolescent Medicine, Univ of Rochester School of Medicine, New York. SA Starnes, MPH, School of Medicine; M Kotelchuck, PhD, Dept of Maternal and Child Health; GH DeFriese, PhD, Cecil G. Sheps Center for Health Svcs Research; FA Loda, MD, Center for Early Adolescence; JA Earp, ScD, Dept of Health Behavior and Health Education, Center for Health Promotion and Disease Prevention, Univ of North Carolina at Chapel Hill. Div of Adolescent and School Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.*

**Editorial Note:** Considerations that are unique to the planning and organization of health services for adolescents include psychosocial development, the need for visible and convenient but confidential services, and the lack of insurance coverage for

**FIGURE 1. Rates\* of comprehensive health programs for adolescents — United States, 1990**



\*Per 100,000 persons aged 13-19 years.

Source: reference 3. Adapted with permission.

*Comprehensive Adolescent Health Services — Continued*

recommended preventive care (4). A variety of model programs have been implemented to meet the comprehensive health needs of adolescents (2); however, only a small proportion of all adolescents are served by these programs and systematic evaluation of such programs has been limited (2,3).

The findings in this report indicate that most programs depend on multiple sources of funding, reflecting the categorical nature of funding for adolescent health services. Access to specific services also varies substantially; for example, many programs identified as comprehensive do not provide comprehensive services on site.

Most adolescent health problems, including HIV infection and other sexually transmitted diseases, are preventable (2). Preventive service guidelines for adolescents\* recommend that confidential health guidance, condoms, and other reproductive-health services be available to youth (5); however, the findings in this report indicate that many comprehensive programs, especially school-based programs, do not provide reproductive-health services. Guidelines that address the range of health services that should be provided are needed for programs seeking to deliver comprehensive, coordinated care to adolescents.<sup>†</sup> More service-delivery programs, stable funding, and better integration of funding and administrative relations among health, education, and other service sectors are also needed if more U.S. adolescents are to have access to appropriate health services.

*References*

1. Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives—full report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service, 1991; DHHS publication no. (PHS)91-50212.
2. Office of Technology Assessment. Adolescent health: summary and policy options. Vol 1. Washington, DC: United States Congress, 1991.
3. Klein JD, Starnes SA, Kotelchuck M, Earp JA, DeFriese GH, Loda FA. Comprehensive adolescent health services in the United States, 1990. Chapel Hill, North Carolina: University of North Carolina at Chapel Hill, 1992.
4. Klein JD, Slap GB, Elster B, Schonberg SK. Access to health care for adolescents: a position paper of the Society for Adolescent Medicine. *J Adolesc Health Care* 1992;24:162–70.
5. Department of Adolescent Health, American Medical Association. Guidelines for adolescent preventive services. Chicago: American Medical Association, 1992.

---

\*Single copies of *Guidelines for Adolescent Preventive Services* are available without charge from the American Medical Association, Department of Adolescent Health, 515 N. State Street, Chicago, IL 60610; telephone (312) 464-5570.

<sup>†</sup>Copies of *Comprehensive Adolescent Health Services in the United States, 1990* are available from the Center for Early Adolescence, University of North Carolina at Chapel Hill, CB #8130, Carr Mill Mall, Carrboro, NC 27510; telephone (919) 966-1148; price: \$15.50.

*Epidemiologic Notes and Reports*

***Salmonella* Serotype Tennessee in Powdered Milk Products and Infant Formula — Canada and United States, 1993**

Since May 1993, three cases of infection with *Salmonella* serotype Tennessee in infants in Canada and the United States have been linked to consumption of contaminated powdered infant formula. This report summarizes preliminary data on isolation of this organism from powdered milk products and alerts laboratories to the possibility that, because this strain may ferment lactose, it may not be identified as *Salmonella*.

Following the isolation of *Salmonella* serotype Tennessee from the stools of two infants in Canada who had consumed Soyalac Powder<sup>®</sup> infant formula in May, the Food and Drug Administration (FDA) isolated *Salmonella* Tennessee from production equipment at the Minnesota plant where the product had been dried, and from cans of the powdered infant formula. In June 1993, one case of infection with *Salmonella* Tennessee occurred in Illinois in an infant who consumed Soyalac Powder<sup>®</sup>. From November 4, 1992, through June 29, 1993, 48 cases of infection with *Salmonella* Tennessee have been reported to CDC; when annualized, this number is not substantially different from the mean of 120 cases reported annually from 1981 through 1991.

On June 28, 1993, FDA ordered a recall of all Soyalac Powder<sup>®</sup> infant formula produced on or after November 4, 1992. FDA has identified additional products that are spray-dried at this plant; these products include Sumacal<sup>®</sup> medical food supplement, Propac<sup>®</sup> protein supplement, canned Medibase<sup>®</sup> medical meal replacement, Kresto Denia<sup>®</sup> powdered milk, Enercal<sup>®</sup> diet beverage, Enercal Plus<sup>®</sup>, and Promil<sup>®</sup> weaning formula. No cases of illness have been linked to these products. FDA is working with plant officials to determine whether any other products were dried or packaged at this plant during this time. No spray-dried products have been distributed from this plant since June 7, 1993. FDA has requested recall of all products spray-dried at this plant since November 4, 1992. More detailed product information is available from the Division of Emergency and Epidemiological Operations, FDA, telephone (301) 443-1240.

*Reported by: KK Louie, REHO, Boundary Health Unit, Surrey, British Columbia; AMPaccagnella, WD Osei, British Columbia Center for Disease Control, Vancouver; H Lior, MSc, Chief, National Laboratory for Enteric Pathogens, Laboratory Center for Disease Control, Ottawa, Ontario, Canada. BJ Francis, MD, State Epidemiologist, Illinois Dept of Public Health. MT Osterholm, PhD, State Epidemiologist, Minnesota Dept of Health. Minneapolis District, Center for Food Safety and Applied Nutrition, Food and Drug Administration. Foodborne and Diarrheal Diseases Br, Div of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, CDC.*

**Editorial Note:** Outbreaks of salmonellosis caused by powdered milk products have been reported in the United States (1) and elsewhere (2,3). The isolates of *Salmonella* Tennessee that were identified from the three infants described in this report are atypical of salmonellae because most colonies ferment lactose and, therefore, may not be detected by clinical laboratories that use media or methods that identify salmonellae based on absence of lactose fermentation.

To isolate this organism, plating media that include an indicator of hydrogen sulfide (H<sub>2</sub>S) production, such as bismuth sulfite (BS) agar, Hektoen enteric (HE) agar, or xylose-lysine-deoxycholate (XLD) agar, should be used. BS does not contain lactose, so typical H<sub>2</sub>S-producing (black) colonies can be selected from this medium. Both HE



*Salmonella* — Continued

and XLD contain an indicator of H<sub>2</sub>S production, as well as lactose; selection of colonies from these media should be based on H<sub>2</sub>S production rather than absence of lactose fermentation. At CDC, H<sub>2</sub>S production by this strain was detected more easily on HE than on XLD. Use of either BS or HE is recommended for recovery of this strain. XLD agar should be used only if other media are not available.

To screen colonies selected from isolation plates, lysine-iron agar (LIA) is recommended because the reaction produced by lactose-fermenting salmonellae in this medium is typical and because H<sub>2</sub>S produced by lactose-fermenting organisms can be detected. Triple sugar iron agar (TSI) or other media that depend on lactose fermentation to identify suspect salmonellae should not be used. H<sub>2</sub>S production may not be detected on TSI because of acidic conditions caused by fermentation of lactose. Automated test systems should be used with caution, since lactose-fermenting salmonellae tested at CDC in several such systems were sometimes identified incorrectly. This particular strain was correctly identified as *Salmonella* by the Analytab Products' API 20E<sup>®\*</sup> system.

CDC requests that health-care providers and public health departments continue routine reporting to the *Salmonella* surveillance system; that all *Salmonella* serogroup C<sub>1</sub> (of which *Salmonella* Tennessee is a member) isolates be serotyped; that persons infected with *Salmonella* Tennessee be questioned specifically about consumption of powdered milk products or infant formula; and that, until August 15, 1993, new cases of infection with *Salmonella* Tennessee, whether lactose fermenting or nonlactose fermenting, be reported promptly to the state health department.

*References*

1. Collins RN, Treger MD, Goldsby JB, Boring JR III, Coohon DB, Barr RN. Interstate outbreak of *Salmonella newbrunswick* infection traced to powdered milk. *JAMA* 1968;203:838-44.
2. Weissman JB, Deen RMAD, Williams M, Swanston N, Ali S. An island-wide epidemic of salmonellosis in Trinidad traced to contaminated powdered milk. *West Indian Med J* 1977; 26:135-43.
3. Rowe B, Begg NT, Hutchinson DN, et al. *Salmonella* Ealing infections associated with consumption of infant dried milk. *Lancet* 1987;2:900-3.

\*Use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Service or the U.S. Department of Health and Human Services.

Emerging Infectious Diseases**Update: Hantavirus Infection —  
United States, 1993**

An outbreak of respiratory illness associated with hantavirus infection continues to be investigated by state health departments in Arizona, Colorado, New Mexico, and Utah; the Indian Health Service; and CDC, with the assistance of the Navajo Nation Division of Health (1-4). This report updates information regarding the outbreak and presents information on a case of unexplained adult respiratory distress syndrome (ARDS) in a person who resided in eastern Texas.

*Hantavirus Infection — Continued*

Laboratory evidence of acute hantavirus infection has been confirmed in 16 patients who had onset of illness from January 1 through June 30, 1993. Of these 16 cases, 11 occurred in New Mexico, four in Arizona, and one in Colorado; 12 occurred among persons aged 20–40 years. Twelve patients have died. Similar illnesses in an additional 25 persons in the four-state area, 10 of whom died, are being investigated for possible hantavirus infection.

In June 1993, a fatal case of ARDS occurred following a prodrome of fever, myalgias, and shortness of breath in a previously healthy 58-year-old woman who lived in eastern Texas. The woman had not traveled outside eastern Texas during the 3 months before her illness. During her hospitalization, diagnostic evaluation, including blood and sputum cultures and a transbronchial lung biopsy, did not reveal the cause of her illness. A serologic test conducted at CDC on a single serum specimen revealed an elevated hantavirus immunoglobulin M enzyme-linked immunosorbent assay titer. The Texas Department of Health and CDC are continuing to investigate this illness by examining clinical materials using additional techniques and seeking evidence of hantavirus infection in rodents in the vicinity.

Except for illnesses in the Texas patient described in this report and in a person who had traveled to the four-state area in 1992 (4), no evidence of hantavirus infection has been detected in serologic tests conducted at CDC on specimens from 22 other persons with unexplained ARDS who resided outside the four-state area.

*Reported by: MJ Burkhardt, MPH, Secretary of Health, N Kalishman, MD, M Gallaher, MD, R Voorhees, MD, M Samuel, DrPH, M Tanuz, G Simpson, MD, L Hughes, PhD, E Umland, MD, G Oty, MS, L Nims, MS, CM Sewell, DrPH, State Epidemiologist, New Mexico Dept of Health. K Komatsu, MPH, C Kioski, MPH, K Fleming, MA, J Doll, PhD, C Levy, MS, TM Fink, P Murphy, B England, MD, M Smolinski, MD, B Erickson, PhD, W Slanta, L Sands, DO, Acting State Epidemiologist, Arizona Dept of Health Svcs. P Shillam, MSPH, RE Hoffman, MD, State Epidemiologist, Colorado Dept of Health. S Lanser, MPH, CR Nichols, MPA, State Epidemiologist, Utah Dept of Health. B Ray, KA Hendricks, MD, DM Simpson, PhD, State Epidemiologist, Texas Dept of Health. L Hubbard-Pourier, MPH, Div of Health, Navajo Nation, Window Rock, Arizona. J Cheek, MD, A Craig, MD, R Haskins, MPH, B Muneta, MD, B Tempest, MD, M Carroll, MD, LA Shands, MPH, JP Sarisky, MPH, RE Turner, P Bohan, MS, Indian Health Svc. Div of Field Epidemiology, Epidemiology Program Office; Div of Bacterial and Mycotic Diseases, Div of Vector-Borne Infectious Diseases, Scientific Resources Program, and Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC.*

**Editorial Note:** The findings of the investigation described in this report suggest that acute hantavirus infection occurred in a resident of eastern Texas. This case suggests that ARDS associated with acute hantavirus infection can occur in areas outside the southwestern United States. CDC continues to work with state health departments to investigate cases of unexplained ARDS.

The current outbreak appears to be caused by a newly recognized hantavirus associated with *Peromyscus maniculatus* (deer mouse). Previously, two well-characterized hantaviruses had been isolated from different species in the United States: Seoul virus from *Rattus norvegicus* (Norway rat) and Prospect Hill virus from *Microtus pennsylvanicus* (meadow vole) (5). Antibodies reactive with these viruses have been detected in serum specimens from rodents and humans from many areas of the United States (5).

A previous report suggests that the prevalence of hantavirus-specific antibodies is low in humans in the United States (6). However, examination of the association of hantavirus infection with human disease in the United States has been limited and

*Hantavirus Infection —Continued*

focused on renal disease, which is characteristic of previously described hantavirus syndromes, but not on pulmonary disease, which is characteristic of the syndrome in the current outbreak (7). In one recent study, serologic evidence of past hantavirus infection was associated with a diagnosis of hypertensive renal disease (6). Additional research is needed to define the distribution and manifestations of hantavirus infections in the United States.

*References*

1. CDC. Outbreak of acute illness—southwestern United States, 1993. *MMWR* 1993;42:421–4.
2. CDC. Update: outbreak of hantavirus infection—southwestern United States, 1993. *MMWR* 1993;42:441–3.
3. CDC. Update: outbreak of hantavirus infection—southwestern United States, 1993. *MMWR* 1993;42:477–9.
4. CDC. Update: outbreak of hantavirus infection—southwestern United States, 1993. *MMWR* 1993;42:495–6.
5. Yanagihara R. Hantavirus infection in the United States: epizootiology and epidemiology. *Rev Infect Dis* 1990;12:449–57.
6. Glass GE, Watson AJ, LeDuc JW, Kelen GD, Quinn TC, Childs JE. Infection with a ratborne hantavirus in US residents is consistently associated with hypertensive renal disease. *J Infect Dis* 1993;167:614–20.
7. LeDuc JW, Childs JE, Glass GE, Watson AJ. Hantaan (Korean hemorrhagic fever) and related rodent zoonoses. In: Morse SS, ed. *Emerging viruses*, 1993. New York: Oxford University Press, 1993:149–58.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available on a paid subscription basis from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 783-3238.

The data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the succeeding Friday. Inquiries about the *MMWR* Series, including material to be considered for publication, should be directed to: Editor, *MMWR* Series, Mailstop C-08, Centers for Disease Control and Prevention, Atlanta, GA 30333; telephone (404) 332-4555.

Acting Director, Centers for Disease Control  
and Prevention

Walter R. Dowdle, Ph.D.

Acting Director, Epidemiology Program Office

Barbara R. Holloway, M.P.H.

Editor, *MMWR* Series

Richard A. Goodman, M.D., M.P.H.

Managing Editor, *MMWR* (weekly)

Karen L. Foster, M.A.

Writers-Editors, *MMWR* (weekly)

David C. Johnson

Patricia A. McGee

Darlene D. Rumph

Caran R. Wilbanks

---

☆U.S. Government Printing Office: 1993-733-131/83015 Region IV

---